Chinese Biotech Firms Face Uncertain Future as Global Drug Giants Tighten Licensing Budgets

According to analysts, out-licensing agreements have emerged as the main source of funding for financially constrained Chinese biotech firms, outpacing both IPOs and pre-IPO fundraising. In the first half of the year, unprecedented cross-border deals enabled some previously unprofitable Chinese biotech companies to turn a profit. Nevertheless, multinational pharmaceutical firms are indicating intentions to reduce their deal budgets, which raises concerns about the viability of depending on international licensing revenue. Jefferies' Asia healthcare research head, Cui Cui, remarked that Chinese biotech assets are still relatively inexpensive compared to global counterparts, suggesting that if large pharmaceutical companies become more discerning, these assets could become even more appealing. Macquarie Capital's Tony Ren emphasized the significance of these deals in relation to IPO earnings. Deloitte's data reveals that healthcare and pharmaceutical companies secured HK$14.1 billion (US$1.8 billion) through 11 listings in Hong Kong during the first half, while six biotech firms raised a total of 2.12 billion yuan on mainland China's A-share market, as reported by EY. The trend toward out-licensing underscores the financial challenges faced by Chinese biotech companies, yet the potential budget constraints from global drug companies may influence future deal activity.